This Ro company profile covers the company's valuation, revenue, funding rounds, investors and history. Ro works in healthcare, with a focus on direct-to-patient telehealth and pharmacy. It was founded in 2017 and is headquartered in New York, New York, United States. Its latest valuation on record is US$7 billion (February 2022). Every figure links to a public source, and anything the company hasn't disclosed is marked as such.
Revenue
| Metric | Value | As of | Source |
|---|---|---|---|
| Estimated revenue | About US$598 million annualised in 2024, up about 66% (third-party estimate) | 2024 | Sacra |
Funding history
| Date | Round | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Feb 2022 | Equity round | US$150M | US$7B | ShawSpring Partners (lead); General Catalyst, FirstMark, TQ Ventures | Sacra |
| Mar 2021 | Series D | US$500M | US$5B | See source | MobiHealthNews |
Ro timeline
Key dates from the sources on this page, oldest first. Metric snapshots are listed after the funding events.
- 2017 — Ro is founded in New York by Zachariah Reitano (CEO), Rob Schutz and Saman Rahmanian.
- Mar 2021 — Series D: US$500M, valuing the company at US$5B.
- Feb 2022 — Equity round: US$150M, valuing the company at US$7B. Investors: ShawSpring Partners (lead); General Catalyst, FirstMark, TQ Ventures.
- 2024 — Estimated revenue: About US$598 million annualised in 2024, up about 66% (third-party estimate).
Investors
Overview
Ro is a direct-to-patient healthcare company. Patients complete an online visit with a licensed clinician, who can prescribe treatment, and Ro delivers medications to their door through its pharmacy network. It started with treatments for men's health under the Roman brand, then added women's health (Rory), smoking cessation, fertility testing and primary care services. Since 2023, its biggest growth driver has been weight loss: Ro offers GLP-1 medications such as Wegovy and Zepbound alongside clinical support, coaching and insurance navigation.
Zachariah Reitano, the CEO, Rob Schutz and Saman Rahmanian founded Ro in New York in 2017. Reitano has spoken about his own experience with health conditions as a teenager as an inspiration for building convenient, stigma-free care. Ro has become one of the most valuable consumer telehealth companies in the US.
Products and services
- Weight loss: GLP-1 programmes including clinician visits, prescriptions, insurance coverage checks and support.
- Roman: men's health treatments, such as for hair loss and sexual health.
- Rory: women's health treatments, including for menopause.
- Other care: treatments for skin, smoking cessation and other conditions.
- Pharmacy and logistics: fulfilment through its own and partner pharmacies.
Funding
Ro raised from investors including General Catalyst, FirstMark Capital, TQ Ventures, Initialized Capital and SignalFire. In March 2021 it raised a US$500 million Series D at a US$5 billion valuation. In February 2022 it raised US$150 million at a US$7 billion valuation, led by ShawSpring Partners, bringing total primary funding to about US$1 billion. We haven't found a newer priced round, so the 2022 figure should be treated as historical.
Revenue
Ro doesn't publish financial statements. Research firm Sacra estimated its annualised revenue at about US$598 million in 2024, up about 66%, driven largely by weight loss. We list this as a third-party estimate and show revenue as not disclosed in the fact tiles.
Business model
Ro earns revenue from subscriptions and medication sales, with some services billed to insurance. For GLP-1 programmes, patients pay a membership fee for care and support, while medications may be covered by insurance or bought directly at discounted cash prices from drugmakers' programmes. Its marketing, including high-profile campaigns with celebrities such as Serena Williams, aims to build trust in a crowded market.
Competition
Ro competes with telehealth companies such as Hims & Hers, Noom, WeightWatchers and LifeMD; with drugmakers' own direct-to-consumer platforms, such as Eli Lilly's LillyDirect and Novo Nordisk's NovoCare; with traditional doctors and pharmacies; and with compounding pharmacies that sold cheaper versions of GLP-1 drugs during shortages. Its advantages are its brand, clinical operations and partnerships for branded medications.
Ro at a glance
Ro is a New York telehealth company founded in 2017 by Zachariah Reitano, Rob Schutz and Saman Rahmanian. It provides online care and medication delivery across men's and women's health and weight loss. It raised US$150 million at a US$7 billion valuation in February 2022, led by ShawSpring, and Sacra estimated its 2024 annualised revenue at about US$598 million.
Timeline
- 2017: founded; launches Roman.
- 2019–2020: adds women's health and other services; telehealth demand rises during the pandemic.
- March 2021: raises US$500 million at US$5 billion.
- February 2022: raises US$150 million at US$7 billion.
- 2023–2025: GLP-1 weight loss becomes its largest growth driver.
The GLP-1 boom
GLP-1 medications, originally developed for type 2 diabetes, have proven highly effective for weight loss, creating one of the largest markets in pharmaceutical history. Demand far outstripped supply in 2023 and 2024, and many patients turned to telehealth companies for access. Insurance coverage for weight loss remains inconsistent, and prices are high, though drugmakers have launched lower cash prices for direct purchasers. Telehealth companies have become important distribution channels, but they depend on drug supply, pricing and regulation.
Who uses Ro
Ro's patients are adults seeking convenient care for conditions they may find awkward to discuss in person, and people seeking medical weight loss support without long waits for specialist appointments.
Risks
- Drug pricing and supply: changes affect GLP-1 programme economics.
- Regulation: telehealth prescribing rules and advertising scrutiny can change.
- Competition: drugmakers and rivals sell directly to patients.
Questions for patients
- What does the membership include, and what do medications cost?
- Does your insurance cover the treatment?
- How is ongoing care and monitoring provided?
How Ro's care model works
A patient starts by answering a medical questionnaire online, sometimes followed by a video or message-based consultation with a licensed clinician in their state. If treatment is appropriate, the clinician prescribes it, and medication ships to the patient's home. Patients can message their care team, and some programmes include lab tests and follow-up check-ins. For weight loss, Ro also helps patients navigate insurance coverage, which can be complex for GLP-1 drugs. This model reduces the time and embarrassment some patients associate with in-person visits, but critics question whether online-first care can be as thorough as traditional care for complex conditions.
Valuation context
If third-party estimates of roughly US$600 million in annualised revenue in 2024 are accurate, Ro's 2022 valuation of US$7 billion would represent a much lower multiple today than when it was set. Listed competitor Hims & Hers has seen its market value swing widely with GLP-1 news, showing how sensitive the sector is to drug supply and pricing.
Typical Ro customers
Ro's patients are adults across the US, many of whom prefer the convenience and privacy of online care, including people seeking treatment for weight, hair loss, sexual health, menopause and skin conditions.
Its marketing and celebrity partnerships have helped build national brand awareness.
Latest developments (October 2026)
Ro has kept adding weight-loss treatment options. In 2026 it began offering Eli Lilly's oral drug Foundayo and the Zepbound KwikPen, and launched Wegovy savings with Novo Nordisk, according to its press page. In January 2026 it also announced a research collaboration with Amgen on barriers to obesity care, reported by MarketScreener. No new valuation has been disclosed. See our health tech unicorns guide.
What to watch
Watch GLP-1 pricing, partnerships with drugmakers, new funding or IPO plans, and regulatory changes. Our guide to healthcare AI startups covers related companies.
Takeaways
Patients can access convenient online care and treatment delivery. Founders can see how a new drug category can transform a company. Investors should treat the 2022 valuation as historical given its fast revenue growth.
Sources
Every figure on this page comes from the public sources below. Where sources disagreed, we used the company's own announcement or a primary news report. Private-company data changes; check the date beside each figure.
Frequently asked questions
What does Ro do?
Ro is a healthcare / direct-to-patient telehealth and pharmacy company headquartered in New York, New York, United States. It was founded in 2017.
What is Ro's valuation?
Ro was valued at US$7 billion as of February 2022, according to Sacra. Private company valuations are set at funding rounds or share sales and can change significantly between them.
How much revenue does Ro make?
Ro is a private company and has not publicly disclosed its revenue. Figures on third-party sites are usually modelled estimates rather than numbers reported by the company.
What was Ro's latest funding round?
The most recent financing we have verified is a equity round in Feb 2022: US$150M, at a valuation of US$7B. Source: Sacra.
Who are Ro's investors?
Investors named in public announcements include ShawSpring Partners, General Catalyst, FirstMark Capital, TQ Ventures, Initialized Capital and SignalFire.
Who founded Ro?
Ro was founded in 2017 by Zachariah Reitano (CEO), Rob Schutz and Saman Rahmanian.
Is Ro a public company?
No. Ro is a private company (private, venture backed), so its shares are not traded on a stock exchange and it isn't required to publish its financial results.
Where is Ro headquartered?
Ro is headquartered in New York, New York, United States.